# Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

> **NCT05475366** · NA · RECRUITING · sponsor: **Institut Curie** · enrollment: 85 (estimated)

## Conditions studied

- Carcinoma, Pancreatic Ductal
- Prognosis

## Interventions

- **OTHER:** Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC
- **OTHER:** Biomarkers of tumor signatures (translational studies)

## Key facts

- **NCT ID:** NCT05475366
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-12
- **Primary completion:** 2028-12-11
- **Final completion:** 2028-12-11
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05475366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05475366, "Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05475366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*